AR102595A1 - Anticuerpos anti-ang2 y métodos de utilización - Google Patents
Anticuerpos anti-ang2 y métodos de utilizaciónInfo
- Publication number
- AR102595A1 AR102595A1 ARP150103648A ARP150103648A AR102595A1 AR 102595 A1 AR102595 A1 AR 102595A1 AR P150103648 A ARP150103648 A AR P150103648A AR P150103648 A ARP150103648 A AR P150103648A AR 102595 A1 AR102595 A1 AR 102595A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- antibody
- sequence seq
- variable domain
- acid residue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un anticuerpo que se une específicamente a ANG2 humano, en el que el anticuerpo comprende: (a) un RHV-H1 que comprende la secuencia de aminoácidos SEC ID nº 20, (b) un RHV-H2 que comprende la secuencia de aminoácidos SEC ID nº 21, y (c) un RHV-H3 que comprende la secuencia de aminoácidos SEC ID nº 23. Reivindicación 5: Un anticuerpo que se une específicamente a ANG2 humano, en el que el anticuerpo: i) comprende un dominio variable de cadena pesada que presenta una secuencia de aminoácidos SEC ID nº 19 superior a 70% y un dominio variable de cadena ligera que presenta una identidad de secuencia respecto a SEC ID nº 6 superior a 70%, ii) presenta en el dominio variable de cadena pesada en la posición 28 el residuo aminoácido asparagina (N), en la posición 30 el residuo aminoácido alanina (A), en la posición 100b el residuo aminoácido prolina (P) y en la posición 100j el residuo aminoácido alanina (A) y en el dominio variable de cadena ligera en la posición 51 el residuo aminoácido treonina (T) (numeración según Kabat), y iii) el anticuerpo presenta un valor de EC₅₀ inferior para la inhibición de la unión de ANG2 a su receptor Tie2 en un ensayo celular utilizando células HEK293 que expresaban establemente Tie2 humano determinado utilizando un ELISA de fosforilación de Tie2 en comparación con un anticuerpo que comprende un dominio variable de cadena pesada que presenta la secuencia SEC ID nº 19 y un dominio variable de cadena ligera que presenta la secuencia SEC ID nº 6 ó a la secuencia SEC ID nº 33. Reivindicación 10: Formulación farmacéutica que comprende el anticuerpo según cualquiera de las reivindicaciones 1 a 9 y opcionalmente un portador farmacéuticamente aceptable. Reivindicación 14: Utilización según cualquiera de las reivindicaciones 12 y 13, en el que el medicamento está destinado al tratamiento de una enfermedad vascular ocular, preferentemente al tratamiento de la degeneración macular. Reivindicación 15: Utilización según cualquiera de las reivindicaciones 12 y 13, en el que el medicamento está destinado al tratamiento del cáncer, preferentemente al tratamiento de un cáncer neoangiogéníco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192524 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102595A1 true AR102595A1 (es) | 2017-03-08 |
Family
ID=51868115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103648A AR102595A1 (es) | 2014-11-10 | 2015-11-09 | Anticuerpos anti-ang2 y métodos de utilización |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10538585B2 (es) |
| EP (1) | EP3218398A1 (es) |
| JP (2) | JP2017534644A (es) |
| KR (1) | KR20170082594A (es) |
| CN (1) | CN107001456A (es) |
| AR (1) | AR102595A1 (es) |
| AU (1) | AU2015345321A1 (es) |
| BR (1) | BR112017009790A2 (es) |
| CA (1) | CA2963606A1 (es) |
| IL (1) | IL251477A0 (es) |
| MX (1) | MX2017005642A (es) |
| SG (1) | SG11201703458UA (es) |
| TW (1) | TW201630935A (es) |
| WO (1) | WO2016075035A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2417156T3 (pl) | 2009-04-07 | 2015-07-31 | Roche Glycart Ag | Trójwartościowe, bispecyficzne przeciwciała |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| WO2019122054A1 (en) * | 2017-12-22 | 2019-06-27 | F. Hoffmann-La Roche Ag | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
| WO2019164219A1 (en) * | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| JP2023530187A (ja) | 2020-06-22 | 2023-07-13 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ａｎｇ－２抗体とその用途 |
| MX2023001977A (es) * | 2020-08-19 | 2023-05-04 | Pharmabcine Inc | Anticuerpo modificado y método para la fabricación del mismo. |
| CN115772544B (zh) * | 2021-09-06 | 2024-04-26 | 合肥星眸生物科技有限公司 | 抗vegf-a和ang-2的aav载体 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117820490A (zh) * | 2022-09-28 | 2024-04-05 | 科兴生物制药股份有限公司 | Vegf和ang-2双特异性抗体及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| WO2003073982A2 (en) | 2002-02-28 | 2003-09-12 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| CN1780855B (zh) | 2003-01-24 | 2011-03-30 | 应用分子进化公司 | 人IL-1β拮抗剂 |
| US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| CN101861168B (zh) | 2007-05-07 | 2014-07-02 | 米迪缪尼有限公司 | 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用 |
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| ES2398693T3 (es) | 2008-06-06 | 2013-03-21 | Xoma Technology Ltd. | Métodos para el tratamiento de la artritis reumatoide |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| KR20130100125A (ko) | 2010-08-13 | 2013-09-09 | 제넨테크, 인크. | 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체 |
| CN103328511B (zh) | 2010-09-10 | 2016-01-20 | 埃派斯进有限公司 | 抗-IL-1β抗体及其使用方法 |
| JP5972915B2 (ja) * | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Ｆｃ変異体 |
| EP2726088B1 (en) * | 2011-06-29 | 2019-01-02 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
| US9163070B2 (en) | 2012-06-28 | 2015-10-20 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| PE20150361A1 (es) * | 2012-07-13 | 2015-03-14 | Roche Glycart Ag | Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares |
| CA2883807A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| AU2013322564A1 (en) * | 2012-09-28 | 2015-03-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual Angiopoietin-2 / Dll4 binders and anti-VEGF agents |
| MX2015005839A (es) | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| MX2015005874A (es) | 2012-11-09 | 2015-09-10 | Pfizer | Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos. |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| SG10201800492PA (en) * | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| JP6345787B2 (ja) * | 2013-12-20 | 2018-06-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗ａｎｇ２抗体とｃｄ４０アゴニストとの併用療法 |
| CN105899534B (zh) * | 2014-01-15 | 2020-01-07 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| KR20170080584A (ko) * | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| US20190004048A1 (en) * | 2015-06-26 | 2019-01-03 | Amgen Inc. | Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor |
| KR20200013231A (ko) * | 2017-06-02 | 2020-02-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 항암 조합 요법 |
-
2015
- 2015-11-06 KR KR1020177015610A patent/KR20170082594A/ko unknown
- 2015-11-06 WO PCT/EP2015/075876 patent/WO2016075035A1/en active Application Filing
- 2015-11-06 MX MX2017005642A patent/MX2017005642A/es unknown
- 2015-11-06 SG SG11201703458UA patent/SG11201703458UA/en unknown
- 2015-11-06 JP JP2017525007A patent/JP2017534644A/ja active Pending
- 2015-11-06 EP EP15790575.3A patent/EP3218398A1/en not_active Withdrawn
- 2015-11-06 BR BR112017009790A patent/BR112017009790A2/pt not_active Application Discontinuation
- 2015-11-06 AU AU2015345321A patent/AU2015345321A1/en not_active Abandoned
- 2015-11-06 CN CN201580060787.3A patent/CN107001456A/zh active Pending
- 2015-11-06 CA CA2963606A patent/CA2963606A1/en not_active Abandoned
- 2015-11-09 TW TW104136927A patent/TW201630935A/zh unknown
- 2015-11-09 AR ARP150103648A patent/AR102595A1/es unknown
-
2017
- 2017-03-30 IL IL251477A patent/IL251477A0/en unknown
- 2017-05-10 US US15/591,600 patent/US10538585B2/en not_active Expired - Fee Related
-
2020
- 2020-12-11 JP JP2020205947A patent/JP2021050229A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017005642A (es) | 2017-07-24 |
| KR20170082594A (ko) | 2017-07-14 |
| SG11201703458UA (en) | 2017-05-30 |
| BR112017009790A2 (pt) | 2017-12-19 |
| EP3218398A1 (en) | 2017-09-20 |
| JP2021050229A (ja) | 2021-04-01 |
| US20170247441A1 (en) | 2017-08-31 |
| WO2016075035A1 (en) | 2016-05-19 |
| IL251477A0 (en) | 2017-05-29 |
| CN107001456A (zh) | 2017-08-01 |
| JP2017534644A (ja) | 2017-11-24 |
| CA2963606A1 (en) | 2016-05-19 |
| TW201630935A (zh) | 2016-09-01 |
| US10538585B2 (en) | 2020-01-21 |
| AU2015345321A1 (en) | 2017-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| GT201500049A (es) | Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| CO2020014180A2 (es) | Derivados de gip y usos de estos | |
| BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
| DOP2018000102A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| NZ734892A (en) | Amatoxin-antibody conjugates | |
| BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| MX2015016329A (es) | Bloqueador de anticuerpo para la inactivacion de farmaco de proteina. | |
| BR112016011025A2 (pt) | polipeptídeos anticorpo e seus usos | |
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| PE20141149A1 (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |